The new AHA definition of hyperten- sion as a blood pressure >130/80 mmHg was incorporated as the target for initiation of treatment.34 Corticosteroids are not recommended for treating elevated intracranial pressure or cerebral edema in patients with ICH.2 There is limited information on the extent to which this still occurs. Some members of the writing group felt this was a rare occurrence and thus a performance measure focusing on this was likely to have very high compliance already. However, other members were concerned that there was still substan- tial use. Pilot testing during initial implementation may help clarify this. Note that the goal of this performance measure is zero use, and the wording of the measurement set reflects this. A potential challenge is identifying clear documentation in the medical record for an alternative reason (eg, asthma exacerba- tion) if corticosteroids are administered. Conclusions Nine performance measures are proposed as part of this initial AHA/ASA clinical performance measure set for adults hospi- talized with ICH. Six either are existing performance measures that are NQF endorsed (n=2) or have analogous performance measures through other organizations or related disease pro- cesses (n=4). These 6 measures are endorsed for immediate use. Three new measures are proposed, and it is recommended that they be implemented now but also that pilot testing occur during this implementation in case revisions are desirable to improve their feasibility, actionability, and reliability. Many more issues were considered for performance measures but did not meet the criteria for inclusion in this set (Supplemental Table 1). In addition, the writing group recognizes that there are many issues that might be desirable in performance mea- sures but do not currently meet the high evidence standards (Class I or III recommendations) required for consideration. 